



Cite this: *New J. Chem.*, 2015, **39**, 7595

Received (in Montpellier, France)  
5th March 2015,  
Accepted 14th April 2015

DOI: 10.1039/c5nj00555h

www.rsc.org/njc

# Synthesis and catalytic activity of homoleptic lanthanide-tris(cyclopropylethynyl)amidinates†‡

Farid M. Sroor, Cristian G. Hrib, Liane Hilfert, Sabine Busse and Frank T. Edelmann\*

Reactions of anhydrous lanthanide trichlorides,  $\text{LnCl}_3$  ( $\text{Ln} = \text{Nd}, \text{Sm}, \text{Ho}$ ), with 3 equiv. of lithium-cyclopropylethynylamidinates,  $\text{Li}[\text{c-C}_3\text{H}_5\text{-C}\equiv\text{C-C}(\text{NR})_2]$  (**1a**:  $\text{R} = \text{cyclohexyl (Cy)}$ , **1b**:  $\text{R} = \text{}^i\text{Pr}$ ), afforded the new homoleptic lanthanide(III) tris(cyclopropylethynylamidinate) complexes  $[\text{c-C}_3\text{H}_5\text{-C}\equiv\text{C-C}(\text{NCy})_2]_3\text{Sm}$  (**2a**) and  $[\text{c-C}_3\text{H}_5\text{-C}\equiv\text{C-C}(\text{N}^i\text{Pr})_2]_3\text{Ln}$  ( $\text{Ln} = \text{Nd}$  (**2b**),  $\text{Sm}$  (**2c**),  $\text{Ho}$  (**2d**)) as air- and moisture-sensitive crystalline solids in moderate to good isolated yields (45–79%). The formation of unsolvated, homoleptic  $\text{Ln(III)}$  tris(cyclopropylethynylamidinate) was confirmed by an X-ray diffraction study of the holmium derivative  $[\text{c-C}_3\text{H}_5\text{-C}\equiv\text{C-C}(\text{N}^i\text{Pr})_2]_3\text{Ho}$  (**2d**). EI mass spectra of the new rare-earth metal amidinates indicated a significant volatility. An initial catalysis study revealed that these complexes catalyze the addition of terminal alkynes to carbodiimides to give propiolamidines of the type  $\text{R-C}\equiv\text{C-C}(\text{=NR}')(\text{NHR}')$ . The molecular structure of  $N,N'$ -dicyclohexyl-phenylpropiolamidine,  $\text{Ph-C}\equiv\text{C-C}(\text{NCy})(\text{NHCy})$  (**4**), was also determined by X-ray diffraction.

## 1. Introduction

In organolanthanide chemistry, steric saturation of the coordination sphere of the large rare-earth metal cations is generally more important than the electron count. Thus the investigation of new spectator ligands which satisfy the coordination requirements of the lanthanides continues to be of significant current interest. Anionic amidinate ligands of the type  $[\text{RC}(\text{NR}')_2]^-$  ( $\text{R} = \text{H}, \text{alkyl}, \text{aryl}$ ;  $\text{R}' = \text{alkyl}, \text{cycloalkyl}, \text{aryl}, \text{SiMe}_3$ ) have been demonstrated to be highly useful and versatile in that respect. These readily available  $N$ -chelating ligands are generally regarded as steric cyclopentadienyl equivalents.<sup>1</sup> In the case of rare-earth metals, mono-, di- and trisubstituted lanthanide amidinate and guanidinate complexes are all accessible, just like the mono-, di- and tricyclopentadienyl complexes. Over the past *ca.* 25 years, lanthanide amidinates have witnessed an impressive transformation from laboratory curiosities to highly active homogeneous catalysts as well as valuable precursors in materials science. Various rare-earth metal amidinates have been reported to be very efficient homogeneous catalysts *e.g.* for ring-opening polymerization reactions of lactones, the guanylation of amines or the addition of terminal alkynes to carbodiimides.<sup>2</sup> In materials science, homoleptic alkyl-substituted lanthanide tris(amidinate) complexes are often

highly volatile and can be used as promising precursors for ALD (atomic layer deposition) and MOCVD (metal-organic chemical vapor deposition) processes, *e.g.* for the deposition of lanthanide oxide ( $\text{Ln}_2\text{O}_3$ ) or lanthanide nitride ( $\text{LnN}$ ) thin films.<sup>3</sup>

The introduction of alkynyl groups to the central carbon atom in amidines leads to alkynylamidines (or propiolamidines) of the type  $\text{R-C}\equiv\text{C-C}(\text{=NR}')(\text{NHR}')$ . In organic synthesis, alkynylamidines have been frequently employed in the preparation of various heterocycles.<sup>4,5</sup> More recently, alkynylamidines have attracted considerable attention due to their diverse applications in biological and pharmacological systems.<sup>6</sup> Moreover, transition metal and lanthanide alkynylamidinate complexes have been shown to be efficient and versatile catalysts *e.g.* for C-C and C-N bond formation, the addition of C-H, N-H and P-H bonds to carbodiimides as well as  $\epsilon$ -caprolactone polymerization.<sup>7</sup> Thus far, only very few lanthanide complexes containing alkynylamidinate ligands have been described.<sup>7,8</sup> Previously used propiolamidinate ligands include *e.g.* phenylethynyl derivatives  $[\text{Ph-C}\equiv\text{C-C}(\text{NR})_2]^-$  ( $\text{R} = \text{}^i\text{Pr}, \text{}^t\text{Bu}$ )<sup>7a,8</sup> and the trimethylsilyl-acetylene-derived anions  $[\text{Me}_3\text{Si-C}\equiv\text{C-C}(\text{NR})_2]^-$  ( $\text{R} = \text{cyclohexyl (Cy)}, \text{}^i\text{Pr}$ ).<sup>9</sup>

In the course of our ongoing investigation of lanthanide amidinates we recently initiated a study of alkynylamidinates derived from cyclopropylacetylene. The resulting anions  $[\text{c-C}_3\text{H}_5\text{-C}\equiv\text{C-C}(\text{NR})_2]^-$  ( $\text{R} = \text{Cy}, \text{}^i\text{Pr}$ ) represent a potentially useful addition to the current library of amidinate ligands. In a first contribution we described the synthesis and full characterization of the lithium-cyclopropylethynylamidinates  $\text{Li}[\text{c-C}_3\text{H}_5\text{-C}\equiv\text{C-C}(\text{NR})_2]$  (**1a**:  $\text{R} = \text{cyclohexyl (Cy)}$ , **1b**:  $\text{R} = \text{}^i\text{Pr}$ ).<sup>10</sup> These precursors are readily available on a large scale and in high yields using

Chemisches Institut der Otto-von-Guericke-Universität Magdeburg,  
Universitätsplatz 2, 39106 Magdeburg, Germany. E-mail: frank.edelmann@ovgu.de;  
Fax: +49 391 671-2933; Tel: +49 391 675-8327

† Dedicated to Professor Herbert W. Roesky on the occasion of his 80th birthday.

‡ Electronic supplementary information (ESI) available: CIF files of the X-ray structural data for **2d** and **4**. CCDC 1050915 (**2d**) and 1050916 (**4**). For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c5nj00555h




commercially available starting materials. In a subsequent study, their use as precursors for new lanthanide amidinates could be demonstrated by the synthesis of a series of new Ln(III) bis(cyclopropylethynylamidinates). In the case of Ce and Nd, the chloro-bridged dimers  $[(\text{c-C}_3\text{H}_5\text{-C}\equiv\text{C-C}(\text{NR})_2)_2\text{Ln}(\mu\text{-Cl})(\text{THF})_2]$  (Ln = Ce, Nd; R = Cy, <sup>i</sup>Pr) were isolated, whereas the smaller holmium afforded the “ate” complex  $[\text{c-C}_3\text{H}_5\text{-C}\equiv\text{C-C}(\text{NCy})_2]_2\text{-Ho}(\mu\text{-Cl})_2\text{Li}(\text{THF})(\text{OEt}_2)$ . An initial study showed that these complexes effectively catalyze the addition of aniline derivatives to carbodiimides to give *N*-arylguanidines.<sup>11</sup> Herein we report the synthesis and structural characterization of the first homoleptic Ln(III) tris(cyclopropylethynylamidinate) complexes as well as an initial study of their possible use as homogeneous catalysts for the addition of terminal alkynes to carbodiimides.


## 2. Results and discussion

### 2.1 Synthesis and structure

The starting materials used in this study, the lithium-cyclopropylethynylamidinates  $\text{Li}[\text{c-C}_3\text{H}_5\text{-C}\equiv\text{C-C}(\text{NR})_2]$  (**1a**: R = Cy, **1b**: R = <sup>i</sup>Pr), were prepared in a straightforward manner according to Scheme 1 by *in situ*-deprotonation of commercially available cyclopropylacetylene followed by treatment with either *N,N'*-diisopropylcarbodiimide or *N,N'*-dicyclohexylcarbodiimide according to the published procedure. These lithium amidinates can be isolated in the form of stable, crystalline solids as adducts with donor solvent like diethyl ether, THF or



Scheme 1 Synthesis of the lithium-cyclopropylethynylamidinates **1a** and **1b**.



Scheme 2 Synthesis of the Ln(III) tris(cyclopropylethynylamidinates) **2a-d**.


DME (1,2-dimethoxyethane).<sup>10</sup> However, for the reactions with lanthanide trichlorides, the reagents **1a** and **1b** were conveniently prepared in THF solution and used *in situ*.

Subsequent reactions of the lithium-cyclopropylethynylamidinates **1a** and **1b** with anhydrous lanthanide trichlorides,  $\text{LnCl}_3$  (Ln = Nd, Sm, Ho) were carried out in a 1 : 3 molar ratio in THF solutions according to Scheme 2. Evaporation of the volatiles and recrystallization of the crude products from *n*-pentane afforded the new lanthanide(III) tris(cyclopropylethynylamidinate) complexes **2a-d** in moderate (**2b**: 54%, **2c**: 45%, **2d**: 55%) to good (**2a**: 79%) yields. The samarium and holmium derivatives **2a**, **2c**, and **2d** were isolated as yellow, air- and moisture-sensitive crystals, while the neodymium complex **2b** is a green, crystalline solid. All four compounds are highly soluble in THF, diethyl ether, toluene and *n*-pentane. The very high solubility even in non-polar solvents like *n*-pentane certainly accounts for the relatively low yields in the case of complexes **2b-d**. A single-crystal X-ray diffraction study of the holmium derivative **2d** (*vide infra*) confirmed the presence of the expected unsolvated, homoleptic lanthanide(III) tris(cyclopropylethynylamidinate) complex.

All four compounds were characterized by their NMR (<sup>1</sup>H, <sup>13</sup>C) and IR spectra as well as elemental analyses. Despite the paramagnetic nature of the Ln<sup>3+</sup> ions employed here, meaningful NMR spectra could be obtained for all four compounds with the exception of the <sup>1</sup>H NMR spectrum of the Ho<sup>3+</sup> complex **2c**. The data were in good agreement with the formation of unsolvated lanthanide(III) tris(cyclopropylethynylamidinates). No signals attributable to coordinated THF could be observed. The IR spectra of **2a-c** were found to be almost superimposable. IR bands resulting from the C=N stretching vibrations of the N-C-N units appear at around 1606–1612 cm<sup>-1</sup>, whereas very strong bands at 2220–2227 cm<sup>-1</sup> can be assigned to the C≡C vibrations. In all cases the EI mass spectra indicated good volatility of the new homoleptic lanthanide amidinates as they all showed the molecular ions in an intensity range of 20–45% relative intensity.

As a typical representative of the new homoleptic lanthanide tris(amidinates), the holmium derivative **2d** was structurally authenticated through single-crystal X-ray diffraction (Fig. 1).





**Fig. 1** Molecular structure of complex  $[c\text{-C}_3\text{H}_5\text{-C}\equiv\text{CC}(\text{N}^i\text{Pr})_2]_3\text{Ho}$  (**2d**). All hydrogen atoms are omitted for clarity. Selected bond lengths (Å) and angles ( $^\circ$ ): Ho–N1 2.359(3), Ho–N2 2.351(3), Ho–N3 2.348(2), Ho–N4 2.353(3), Ho–N5 2.342(2), Ho–N6 2.383(3), C1–N1 1.312(4), C1–N2 1.327(4), C13–N3 1.333(4), C13–N4 1.331(4), C25–N5 1.333(4), C25–N6 1.324(3), C7–N1 1.481(4), C1–C2 1.461(5), C2–C3 1.182(6), C14–C15 1.185(4), C26–C27 1.184(5), N1–Ho–N2 57.08(9), N3–Ho–N4 57.74(9), N5–Ho–N6 57.14(8), N1–Ho–N3 100.1(11), N2–Ho–N5 98.77(10), N4–Ho–N6 98.74(11), N1–C1–N2 117.0(3), N3–C13–N4 116.9(3), N5–C25–N6 116.6(3).

Pale yellow, block-like single-crystals of **2d** were obtained by cooling of a very concentrated solution in *n*-pentane to  $-30^\circ\text{C}$  over a prolonged period of time. Crystallographic data of **2d** are listed in Table 1, while selected bond lengths and angles are summarized in the caption of Fig. 1. Compound **2d** crystallizes in the triclinic space group  $P\bar{1}$ . The crystal structure determination

clearly confirmed the presence of the first unsolvated homoleptic lanthanide(III) tris(cyclopropylethynylamidinate) complex. The central  $\text{Ho}^{3+}$  ion is coordinated by three chelating  $[c\text{-C}_3\text{H}_5\text{-C}\equiv\text{C-C}(\text{N}^i\text{Pr})_2]^-$  ligands in a highly distorted octahedral fashion. To our knowledge, only three closely related homoleptic  $\text{Ln}(\text{III})$  tris(phenylethynylamidinate) complexes of the type  $[\text{Ph-C}\equiv\text{C-C}(\text{N}^i\text{Pr})_2]_3\text{Ln}$  ( $\text{Ln} = \text{Y},^{8b} \text{Ce},^{8a} \text{Lu}^{8b}$ ) have been reported in the previous literature. All three complexes have also been structurally characterized by X-ray diffraction. The overall structural features of **2d** are very similar to those reported for  $[\text{Ph-C}\equiv\text{C-C}(\text{N}^i\text{Pr})_2]_3\text{Ln}$  ( $\text{Ln} = \text{Y}, \text{Ce}, \text{Lu}$ ). The Ho–N distances in **2d** are in the very narrow range of 2.342(2)–2.383(3) Å. As a result of the lanthanide contraction,<sup>12</sup> these values are virtually identical with those reported for the yttrium(III)-tris(phenylethynylamidinate) complex  $[\text{Ph-C}\equiv\text{C-C}(\text{N}^i\text{Pr})_2]_3\text{Y}$  (Y–N 2.363(4) and 2.356(4) Å). The average N–Ho–N bite angle to the chelating amidinate ligands in **2d** is  $57.33(9)^\circ$ . This is also favorably comparable to the corresponding N–Ln–N angles found in the three phenylethynylamidinates  $[\text{Ph-C}\equiv\text{C-C}(\text{N}^i\text{Pr})_2]_3\text{Ln}$  ( $\text{Ln} = \text{Y}, \text{Ce}, \text{Lu}$ ) and in other homoleptic lanthanide tris(*N,N'*-dialkylamidinates).<sup>1,8</sup> The bond lengths of the triple bonds in the cyclopropylethynyl units in **2d** are 1.182(6) Å (C2–C3), 1.185(4) Å (C14–C15) and 1.184(5) Å (C22–C23).


## 2.2 Catalytic activity

For a first study of the possible catalytic activity of the new  $\text{Ln}(\text{III})$  tris(cyclopropylethynylamidinate) we chose the catalytic addition of alkynes to carbodiimides to give substituted propiolamidines. The lanthanide-catalyzed synthesis of propiolamidines  $\text{R-C}\equiv\text{C-C(=NR')}( \text{NHR}')$  was first reported in 2005 by Hou *et al.* using rare-earth metal half-sandwich complexes as catalysts.

**Table 1** Crystallographic data and structure refinement parameters for compounds **2d** and **4**

	<b>2d</b>	<b>4</b>
Empirical formula	$\text{C}_{36}\text{H}_{57}\text{HoN}_6$	$\text{C}_{21}\text{H}_{28}\text{N}_2$
Formula weight	738.81	308.45
Crystal size ( $\text{mm}^3$ )	$0.40 \times 0.40 \times 0.20$	$0.34 \times 0.23 \times 0.22$
Crystal system	Triclinic	Triclinic
Space group	$P\bar{1}$	$P\bar{1}$
<i>a</i> (Å)	9.776(2)	9.7257(19)
<i>b</i> (Å)	13.149(3)	10.383(2)
<i>c</i> (Å)	16.983(3)	10.558(2)
$\alpha$ ( $^\circ$ )	101.28	70.77
$\beta$ ( $^\circ$ )	105.35	65.92
$\gamma$ ( $^\circ$ )	108.19	70.83
Cell volume ( $\text{\AA}^3$ )	1905.6(7)	895.5(3)
<i>Z</i>	2	2
<i>T</i> ( $^\circ\text{C}$ )	–120	–120
$\lambda$ (Å)	0.71703	0.71703
<i>D</i> <sub>calc</sub> ( $\text{g cm}^{-3}$ )	1.288	1.144
$\mu$ ( $\text{mm}^{-1}$ )	2.106	0.067
<i>F</i> (000)	764	336
Index ranges	$-13 \leq h \leq 13$ $-18 \leq k \leq 18$ $-19 \leq l \leq 23$	$-12 \leq h \leq 11$ $-12 \leq k \leq 12$ $-13 \leq l \leq 12$
Data/restraints/parameters	10 209/38/461	3625/157/267
Goodness-of-fit on <i>F</i> <sup>2</sup>	1.040	1.071
<i>R</i> ( <i>F</i> <sub>o</sub> or <i>F</i> <sub>o</sub> <sup>2</sup> )	0.0343	0.0535
<i>R</i> <sub>w</sub> ( <i>F</i> <sub>o</sub> or <i>F</i> <sub>o</sub> <sup>2</sup> )	0.0908	0.1512
Largest diff. peak and hole ( $\text{e \AA}^{-3}$ )	2.465, –1.743	0.198, –0.223





Scheme 3 Synthesis of  $\text{Ph-C}\equiv\text{C-C}(\text{N}^i\text{Pr})(\text{NH}^i\text{Pr})$  (**3**) using **2a-d** as catalyst.

Table 2 Addition of phenylacetylene to  $N,N'$ -diisopropylcarbodiimide catalyzed by the lanthanide-tris(cyclopropylethynylamidinate)s **2a-d**

Entry <sup>a</sup>	Cat.	Catalyst equiv. (mol%)	Time (h)	Yield <sup>b</sup> of <b>3</b> (%)
1	<b>2a</b>	0.5	1	72
2	<b>2a</b>	1	0.5	85
3	<b>2b</b>	0.5	1	53
4	<b>2b</b>	1	0.5	62
5	<b>2c</b>	0.5	1	54
6	<b>2c</b>	1	0.5	51
7	<b>2d</b>	0.5	1	34
8	<b>2d</b>	1	0.5	27
11	None	0	1	0

<sup>a</sup> General condition: THF as solvent at 60 °C. <sup>b</sup> Isolated yield.

The pre-catalysts used in this study were constrained-geometry-type complexes such as  $[\text{Me}_2\text{Si}(\text{C}_3\text{Me}_4)(\text{NPh})]\text{Y}(\text{CH}_2\text{SiMe}_3)(\text{THF})_2$ . It was found that half-sandwich complexes comprising a propiolamidinate ligand play an important role in the catalytic cycle. Upon treatment with excess acetylene, they release the propiolamidine product.<sup>7a</sup> Most recently, Zhang and Zhou *et al.* employed rare-earth metal alkyl complexes stabilized by the bulky pyrazolylborate ligand  $\text{Tp}^{\text{Me}_2}$  (=hydro-tris(3,5-dimethylpyrazolyl)-borate) as catalysts for the synthesis of  $N$ -aryl-substituted propiolamidines.<sup>7g</sup>


In an initial screening test, we examined the Ln-catalyzed addition of phenylacetylene to  $N,N'$ -diisopropylcarbodiimide in the presence of all four compounds **2a-d** as illustrated in Scheme 3. All four new lanthanide(III)-tris(cyclopropylethynylamidinate)s **2a-d** were used as precatalysts, and the reactions were carried out in concentrated THF solutions at 60 °C. The results are summarized in Table 2. The isolated yields of the known compound  $\text{Ph-C}\equiv\text{C-C}(\text{N}^i\text{Pr})(\text{NH}^i\text{Pr})$  (**3**)<sup>13</sup> varied from 27 to 85% depending of the lanthanide metal employed. Clearly the highest activity was observed for the samarium complex  $[\text{c-C}_3\text{H}_5\text{-C}\equiv\text{C-C}(\text{NCy})_2]_3\text{Sm}$  (**2a**), while the lowest yields were obtained when using the holmium catalyst  $[\text{c-C}_3\text{H}_5\text{-C}\equiv\text{C-C}(\text{N}^i\text{Pr})_2]_3\text{Ho}$  (**2d**). In a control experiment

(Table 2, entry 11), an equimolar mixture of phenylacetylene and  $N,N'$ -diisopropylcarbodiimide were heated in concentrated THF solution at 60 °C for 1 h in the absence of a rare-earth metal compound. Under these conditions, no trace of  $\text{Ph-C}\equiv\text{C-C}(\text{N}^i\text{Pr})(\text{NH}^i\text{Pr})$  (**3**) could be detected in the reaction mixture.

In a second set of experiments, the Ln-catalyzed addition of three different terminal alkynes to both  $N,N'$ -diisopropylcarbodiimide and  $N,N'$ -dicyclohexylcarbodiimide was studied. For these tests, the most active complex  $[\text{c-C}_3\text{H}_5\text{-C}\equiv\text{C-C}(\text{NCy})_2]_3\text{Sm}$  (**2a**) was used as the precatalyst. The reactions were again carried out in THF at 60 °C according to Scheme 4.

As can be seen from the results listed in Table 3, this short screening produced mixed results. Reactions of phenylacetylene with both  $N,N'$ -diisopropylcarbodiimide and  $N,N'$ -dicyclohexylcarbodiimide gave good yields of the hydroacetylenation products **3** and **4**, while cyclopropylacetylene could be added only to  $N,N'$ -dicyclohexylcarbodiimide affording a moderate yield of propiolamidine **5**. In sharp contrast, virtually no reactions were observed when trimethylsilylacetylene was employed. Thus the use of the new homoleptic lanthanide(III)-tris(cyclopropylethynylamidinate)s as catalysts for the addition of terminal acetylenes to carbodiimides appears to be quite limited. Obviously these amidinate complexes cannot seriously compete with previously reported rare-earth metal catalysts comprising cyclopentadienyl<sup>7a</sup> or pyrazolylborate<sup>7g</sup> ligands. These compounds all contain additional  $\sigma$ -alkyl groups such as  $-\text{CH}_2\text{Ph}$  or  $-\text{CH}_2\text{SiMe}_3$  which certainly account for the significantly higher activity of such catalysts systems.<sup>7a,g</sup>

In the course of the present study, the molecular structure of the propiolamidine **4** has been verified by single-crystal X-ray diffraction (*cf.* Table 1). X-Ray-quality single-crystals of **4** were grown by slowly cooling a solution in hot acetonitrile to room temperature. The molecular structure of **4** is shown in Fig. 2. Previously reported crystal structures of propiolamidines include




Scheme 4 Synthesis of alkynylamidines using complex **2a** as catalyst.



**Table 3** Catalytic addition of terminal alkynes to *N,N'*-diisopropylcarbodiimide catalyzed by **2a**

Entry <sup>a,b</sup>	R	R <sub>1</sub>	Time (h)	Product	Yield <sup>c</sup> (%)
1	Ph	<sup>i</sup> Pr	0.5	<b>3</b>	85
2	Ph	Cy	0.5	<b>4</b>	78
3	<i>c</i> -C <sub>3</sub> H <sub>5</sub>	<sup>i</sup> Pr	0.5	—	Traces
4	<i>c</i> -C <sub>3</sub> H <sub>5</sub>	Cy	1	<b>5</b>	48
5	Me <sub>3</sub> Si	<sup>i</sup> Pr	0.5	—	Traces
6	Me <sub>3</sub> Si	Cy	1	—	Traces

<sup>a</sup> General condition: THF as solvent at 60 °C. <sup>b</sup> All reactions carried out using 1.0% mol of **2a**. <sup>c</sup> Isolated yield.



**Fig. 2** Molecular structure of complex of C<sub>6</sub>H<sub>5</sub>-C≡C-C(NCy)(NHCy) (**4**). Most of the hydrogen atoms are omitted for clarity. Selected bond lengths (Å) and angles (°): C1–N1 1.364(2), C1–N2 1.275(2), C1–C2 1.451(2), C2–C3 1.195(3), C10–N1 1.451(3), N1–C1–N2 121.93(17), C10–N1–C1 125.79(15), C16–N2–C1 117.4(4).

those of 4-ClC<sub>6</sub>H<sub>4</sub>-C≡C-C(N<sup>i</sup>Pr)(NH<sup>i</sup>Pr) and 2-ClC<sub>6</sub>H<sub>4</sub>-C≡C-C(N<sup>i</sup>Pr)(NH<sup>i</sup>Pr),<sup>7a</sup> Ph-C≡C-C(NC<sub>6</sub>H<sub>3</sub>Pr<sub>2</sub>-2,6)(NHC<sub>6</sub>H<sub>3</sub>Pr<sub>2</sub>-2,6),<sup>14</sup> and Ph-C≡C-C(NC<sub>6</sub>H<sub>3</sub>Pr<sub>2</sub>-2,6)(NHC<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>-3,4).<sup>7g</sup> The C≡C bond length in **4** is 1.195(3) Å, while the C1–N1 and C1–N2 distance (1.364(2) and 1.275(4) Å) correspond to standard C–N single and double bonds, respectively. As in 4-ClC<sub>6</sub>H<sub>4</sub>-C≡C-C(N<sup>i</sup>Pr)(NH<sup>i</sup>Pr) and 2-ClC<sub>6</sub>H<sub>4</sub>-C≡C-C(N<sup>i</sup>Pr)(NH<sup>i</sup>Pr),<sup>7a</sup> one cyclohexyl substituent points toward the alkynyl group and the other one away, resulting in a transoid conformation around the N–C–N unit. In contrast, a cisoid conformation (both substituents pointing toward the alkynyl group) has been reported for Ph-C≡C-C(NC<sub>6</sub>H<sub>3</sub>Pr<sub>2</sub>-2,6)(NHC<sub>6</sub>H<sub>3</sub>Pr<sub>2</sub>-2,6)<sup>14</sup> and Ph-C≡C-C(NC<sub>6</sub>H<sub>3</sub>Pr<sub>2</sub>-2,6)(NHC<sub>6</sub>H<sub>3</sub>Cl<sub>2</sub>-3,4)<sup>7g</sup> which both contain bulky 2,6-diisopropylphenyl substituents.

### 3. Conclusions

In summarizing the work reported here, we succeeded in the straightforward preparation of a series of new homoleptic lanthanide tris(cyclopropylethynylamidinate) complexes comprising neodymium, samarium, and holmium as central metals. The lithium-cyclopropylethynylamidinate precursors employed in these preparations are readily available in one step from commercially available starting materials. The new complexes **2a–d** are highly soluble even in non-polar solvents such as *n*-pentane. The presence of unsolvated, homoleptic

tris(cyclopropylethynylamidinate) complexes could be verified by an X-ray crystal structure determination of the holmium complex **2d**. An initial catalysis study revealed that the new amidinates effectively catalyze the addition of phenylacetylene to *N,N'*-diisopropylcarbodiimide and *N,N'*-dicyclohexylcarbodiimide but have insufficient activity with other terminal acetylenes.

## 4. Experimental section

### 4.1 General procedures

All experiments were carried out in oven-dried or flame-dried glassware under an inert atmosphere of dry argon employing standard Schlenk and glovebox techniques (<1 ppm O<sub>2</sub>, <1 ppm H<sub>2</sub>O). *n*-Pentane and THF were distilled from sodium/benzophenone under nitrogen atmosphere prior to use. All glassware was oven-dried at 120 °C for at least 24 h, assembled while hot, and cooled under high vacuum prior to use. The starting materials, anhydrous LnCl<sub>3</sub> (Ln = Ce, Nd),<sup>15</sup> and the lithium-cyclopropylethynyl-amidinate precursors **1a** and **1b**<sup>10</sup> were prepared according to the literature methods. <sup>1</sup>H-NMR (400 MHz) and <sup>13</sup>C-NMR (100.6 MHz) were recorded in C<sub>6</sub>D<sub>6</sub> or CDCl<sub>3</sub> solutions on a Bruker DPX 400 spectrometer at 25 °C. Chemical shifts were referenced to TMS. Assignment of signals was made from <sup>1</sup>H–<sup>13</sup>C HSQC 2D NMR experiments. IR spectra were recorded using KBr pellets on a Perkin Elmer FT-IR spectrometer system 2000 between 4000 cm<sup>−1</sup> and 400 cm<sup>−1</sup>. Microanalyses of the compounds were performed using a Leco CHNS 923 apparatus.

### 4.2 Synthesis and characterization of the Ln(m)-tris(cyclopropylethynylamidinates) **2a–d**

[*c*-C<sub>3</sub>H<sub>5</sub>-C≡CC(NCy)<sub>2</sub>]<sub>3</sub>Sm (**2a**). Anhydrous SmCl<sub>3</sub> (1.0 g, 4 mmol) and **1b** (3.3 g, 12 mmol) were charged in a 250 ml Schlenk flask. 100 ml of THF were added and the mixture was stirred 12 h at r.t. to give a clear yellow solution. The solvent was removed under vacuum followed by extraction with *n*-pentane (2 × 15 ml). The clear yellow filtrate was evaporated under vacuum affording **2a** as a pale yellow solid (3.0 g, 79%). <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>, 25 °C): δ = 3.34 (m, 6H, CH, Cy), 1.85 (m, 3H, CH, *c*-C<sub>3</sub>H<sub>5</sub>), 1.56 (br, 12H, CH<sub>2</sub>, Cy), 1.40 (m, 6H, CH<sub>2</sub>, *c*-C<sub>3</sub>H<sub>5</sub>), 0.97–1.32 (m, 18H, CH<sub>2</sub>, Cy), 0.87 (m, 6H, CH<sub>2</sub>, *c*-C<sub>3</sub>H<sub>5</sub>), 0.69 (br, 12H, CH<sub>2</sub>, Cy), −0.21 to −0.12 (q, 6H, CH<sub>2</sub>, Cy), −2.31 (br, 12H, CH<sub>2</sub>, Cy); <sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, C<sub>6</sub>D<sub>6</sub>, 25 °C): δ = 201.9 (NCN), 104.1 (C≡C–C), 73.7 (HC–C≡C), 56.9 (CH, Cy), 35.8 (CH<sub>2</sub>, Cy), 25.5 (CH<sub>2</sub>, Cy), 9.8 (CH<sub>2</sub>, *c*-C<sub>3</sub>H<sub>5</sub>), 1.8 (CH, *c*-C<sub>3</sub>H<sub>5</sub>). MS (EI, *M* = 965.57): *m/z* (%) 965.7(45) [M], 695.4(70) [M–(*c*-C<sub>3</sub>H<sub>5</sub>-C≡CC(NCy)<sub>2</sub>)]<sup>+</sup>, 272.2(80) [*c*-C<sub>3</sub>H<sub>5</sub>-C≡CC(NCy)<sub>2</sub>]<sup>+</sup>, 229.1(58) [*c*-C<sub>3</sub>H<sub>5</sub>-C≡CC(NCy)<sub>2</sub>–(*c*-C<sub>3</sub>H<sub>5</sub>)]<sup>+</sup>, 190.1(63) [*c*-C<sub>3</sub>H<sub>5</sub>-C≡CC(NCy)<sub>2</sub>–(Cy) + 2H]<sup>+</sup>, 177(100) [*c*-C<sub>3</sub>H<sub>5</sub>-C≡CC–NCy + 2H]<sup>+</sup>. IR (KBr): 3668, 3438, 3220, 3012, 2925, 2850, 2665, 2222, 1606, 1469, 1398, 1361, 1174, 1120, 1028, 972, 888, 703, 676, 588 cm<sup>−1</sup>. Anal. calcd for C<sub>54</sub>H<sub>81</sub>N<sub>6</sub>Sm: C, 67.24; H, 8.46; N, 8.71%. Found: C, 67.22; H, 8.51; N, 8.60%.

[*c*-C<sub>3</sub>H<sub>5</sub>-C≡CC(N<sup>i</sup>Pr)<sub>2</sub>]<sub>3</sub>Nd (**2b**). A solution of anhydrous NdCl<sub>3</sub> (1.0 g, 4 mmol) in 30 ml of THF was added to a solution





of **1a** (2.3 g, 12 mmol) in 70 ml of THF. The reaction mixture was heated to 65 °C for 2 h and then stirred at r.t. for 12 h. The solution color changed to blue. Work-up using *n*-pentane as described for **2a** afforded **2b** as green crystals (1.5 g, 54%). <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>, 25 °C): δ = 22.3 (m, 6H, CH-(CH<sub>3</sub>)<sub>2</sub>), 4.10 (m, 3H, CH, c-C<sub>3</sub>H<sub>5</sub>), 2.97 (m, 6H, CH<sub>2</sub>, c-C<sub>3</sub>H<sub>5</sub>), 2.02 (m, 6H, CH<sub>2</sub>, c-C<sub>3</sub>H<sub>5</sub>), -3.55 (m, 36H, CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, C<sub>6</sub>D<sub>6</sub>, 25 °C): δ = 228.6 (NCN), 108.5 (C≡C-C), 65.3 (CH-(CH<sub>3</sub>)<sub>2</sub>), 59.8 (HC-C≡C), 23.1 (CH<sub>3</sub>), 12.1 (CH<sub>2</sub>, c-C<sub>3</sub>H<sub>5</sub>), 2.4 (CH, c-C<sub>3</sub>H<sub>5</sub>). MS (EI, *M* = 715.37): *m/z* (%) 631.6(33) [M-2(<sup>t</sup>Pr)]<sup>+</sup>, 396.4(20) [2(c-C<sub>3</sub>H<sub>5</sub>-C≡CC(N<sup>i</sup>Pr)<sub>2</sub>) + CH<sub>3</sub>]<sup>+</sup>, 381.3(15) [2(c-C<sub>3</sub>H<sub>5</sub>-C≡CC(N<sup>i</sup>Pr)<sub>2</sub>)]<sup>+</sup>, 205.2(50) [(c-C<sub>3</sub>H<sub>5</sub>-C≡CC(N<sup>i</sup>Pr)<sub>2</sub>) + CH<sub>3</sub>]<sup>+</sup>, 177.1(34) [c-C<sub>3</sub>H<sub>5</sub>-C≡CC(N<sup>i</sup>Pr)<sub>2</sub>-CH<sub>3</sub>]<sup>+</sup>, 149.1(17) [c-C<sub>3</sub>H<sub>5</sub>-C≡CC(N<sup>i</sup>Pr)<sub>2</sub>-(c-C<sub>3</sub>H<sub>5</sub>)]<sup>+</sup>. IR (KBr): 3678, 3439, 3220, 3015, 2963, 2867, 2608, 2220, 1865, 1635, 1591, 1498, 1382, 1332, 1169, 811, 716, 692, 530, 445 cm<sup>-1</sup>. Anal. calcd for C<sub>36</sub>H<sub>57</sub>N<sub>6</sub>Nd: C, 60.16; H, 7.93; N, 11.69%. Found: C, 60.25; H, 7.92; N, 11.52%.

[c-C<sub>3</sub>H<sub>5</sub>-C≡CC(N<sup>i</sup>Pr)<sub>2</sub>]<sub>3</sub>Sm (**2c**). A reaction of anhydrous SmCl<sub>3</sub> (1.0 g, 4 mmol) with **1a** (2.3 g, 12 mmol) following the procedure described for **2a** afforded **2d** as a yellow, crystalline solid (1.6 g, 55%). <sup>1</sup>H NMR (400 MHz, C<sub>6</sub>D<sub>6</sub>, 25 °C): δ = 3.60 (m, 6H, CH-(CH<sub>3</sub>)<sub>2</sub>), 1.81 (m, 3H, CH, c-C<sub>3</sub>H<sub>5</sub>), 1.37 (m, 6H, CH<sub>2</sub>, c-C<sub>3</sub>H<sub>5</sub>), 0.89 (m, 6H, CH<sub>2</sub>, c-C<sub>3</sub>H<sub>5</sub>), -0.47 (m, 36H, CH<sub>3</sub>); <sup>13</sup>C{<sup>1</sup>H} NMR (100.6 MHz, C<sub>6</sub>D<sub>6</sub>, 25 °C): δ = 201.6 (NCN), 104.5 (C≡C-C), 73.5 (HC-C≡C), 48.3 (CH-(CH<sub>3</sub>)<sub>2</sub>), 25.1 (CH<sub>3</sub>), 9.7 (CH<sub>2</sub>, c-C<sub>3</sub>H<sub>5</sub>), 1.7 (CH, c-C<sub>3</sub>H<sub>5</sub>). MS (EI, *M* = 725.38): *m/z* (%) 726.4(20) [M]<sup>+</sup>, 710.5(23) [M-CH<sub>3</sub>]<sup>+</sup>, 533.3(10) [M-c-C<sub>3</sub>H<sub>5</sub>-C≡CC(N<sup>i</sup>Pr)<sub>2</sub> + H]<sup>+</sup>, 343.1(32) [M-2(c-C<sub>3</sub>H<sub>5</sub>-C≡CC(N<sup>i</sup>Pr)<sub>2</sub>)]<sup>+</sup>, 327.1(22) [M-2(c-C<sub>3</sub>H<sub>5</sub>-C≡CC(N<sup>i</sup>Pr)<sub>2</sub>)-CH<sub>3</sub>]<sup>+</sup>, 177.1(58) [c-C<sub>3</sub>H<sub>5</sub>-C≡CC(N<sup>i</sup>Pr)<sub>2</sub>-CH<sub>3</sub>]<sup>+</sup>, 149.1(20) [c-C<sub>3</sub>H<sub>5</sub>-C≡CC(N<sup>i</sup>Pr)<sub>2</sub>-(c-C<sub>3</sub>H<sub>5</sub>)]<sup>+</sup>. IR (KBr): 3653, 3440, 3096, 3015, 2963, 2866, 2608, 2221, 1612, 1466, 1330, 1263, 1210, 1185, 1052, 967, 875, 811, 707, 529, 472 cm<sup>-1</sup>. Anal. calcd for C<sub>36</sub>H<sub>57</sub>N<sub>6</sub>Sm: C, 59.70; H, 7.93; N, 11.60%. Found: C, 59.80; H, 7.83; N, 11.55%.

[c-C<sub>3</sub>H<sub>5</sub>-C≡CC(N<sup>i</sup>Pr)<sub>2</sub>]<sub>3</sub>Ho (**2d**). A solution of anhydrous HoCl<sub>3</sub> (1.0 g, 3.7 mmol) in 30 ml of THF was added to a solution of **1a** (2.2 g, 11.1 mmol) in 60 ml of THF. The reaction mixture was heated to 65 °C for 3 h and then stirred at r.t. for 12 h. The solvent was removed under vacuum followed by extraction with pentane 2 × 15 ml to give a clear bright-yellow solution. The filtrate was concentrated to ca. 5 ml. Crystallization at -30 °C for three months afforded **2d** as pale yellow crystals (1.2 g, 45%). Due to the strongly paramagnetic nature of the Ho<sup>3+</sup> ion, no meaningful <sup>1</sup>H NMR data could be obtained. <sup>13</sup>C NMR (100.6 MHz, C<sub>6</sub>D<sub>6</sub>, 25 °C): δ = 224.8 (NCN), 158.8 (C≡C-C), 62.7 (HC-C≡C), 50.4 (CH-(CH<sub>3</sub>)<sub>2</sub>), 29.8 (CH<sub>3</sub>), 26.5 (CH<sub>3</sub>), 8.7 (CH<sub>2</sub>, c-C<sub>3</sub>H<sub>5</sub>), 0.35 (CH, c-C<sub>3</sub>H<sub>5</sub>). MS (EI, *M* = 738.39): *m/z* (%) 738.5(35) [M], 723.5(50) [M-CH<sub>3</sub>]<sup>+</sup>, 695.5(32) [M-2CH<sub>3</sub>]<sup>+</sup>, 547.3(36) [M-c-C<sub>3</sub>H<sub>5</sub>-C≡CC(N<sup>i</sup>Pr)<sub>2</sub>]<sup>+</sup>, 177.1(100) [c-C<sub>3</sub>H<sub>5</sub>-C≡CC(N<sup>i</sup>Pr)<sub>2</sub>-CH<sub>3</sub>]<sup>+</sup>, 149.1(43) [c-C<sub>3</sub>H<sub>5</sub>-C≡CC(N<sup>i</sup>Pr)<sub>2</sub>-(c-C<sub>3</sub>H<sub>5</sub>)]<sup>+</sup>. IR (KBr): 3440, 3219, 2964, 2932, 2869, 2227, 1636, 1612, 1486, 1375, 1315, 1260, 1179, 1031, 984, 879, 812, 505, 468 cm<sup>-1</sup>. Anal. calcd for C<sub>36</sub>H<sub>57</sub>HoN<sub>6</sub>: C, 58.52; H, 7.78; N, 11.38%. Found: C, 58.75; H, 7.33; N, 11.17%.

### 4.3 General procedure for the addition of phenylacetylene to *N,N'*-diisopropylcarbodiimide catalyzed by **2a-d**.

A 100 ml Schlenk flask was charged with phenylacetylene (1.40 ml, 12.8 mmol) and *N,N'*-diisopropylcarbodiimide (2.0 ml, 12.8 mmol) in 20 ml of THF. To the mixture was added the catalyst (**2a**, **2b**, **2c**, or **2d**) (0.5 or 1.0% mmol), dissolved in 5 ml of THF. The resulting mixture was stirred at 60 °C or at room temperature for a fixed time. The solvent was completely removed under vacuum and the product was purified by crystallization from a minimum amount of dry acetonitrile in air to give **3** in yields as shown in Table 2.

### 4.4 General procedure for the addition of terminal alkynes to *N,N'*-diisopropylcarbodiimide catalyzed by **2a**

A 100 ml Schlenk flask was charged with the terminal alkyne (1.0 mmol) and *N,N'*-diisopropylcarbodiimide (1.0 mmol) in 15 ml of THF. To the mixture was added the catalyst **2a** (0.01 mmol), dissolved in 5 ml of THF. The resulting mixture was stirred at 60 °C for a fixed time, as shown in Table 2. The solvent was removed under vacuum and the product was purified by crystallization from a minimum amount of dry acetonitrile in air. The resulting propiolamidines **3-5** were identified through their <sup>1</sup>H and <sup>13</sup>C NMR data (cf. ESI†).<sup>7,14</sup>

### 4.5 X-Ray crystallographic studies

The intensity data of **2d** and **4** were collected on a Stoe IPDS 2T diffractometer with MoKα radiation. The data were collected with the Stoe XAREA<sup>16</sup> program using ω-scans. The space groups were determined with the XRED32<sup>24</sup> program. Absorption corrections were applied using the multi-scan method. The structures were solved by direct methods (SHELXS-97)<sup>17a</sup> and refined by full matrix least-squares methods on *F*<sup>2</sup> using SHELXL-97.<sup>17b</sup> Data collection parameters are given in Table 1.

## Acknowledgements

Financial support by the Otto-von-Guericke-Universität Magdeburg is gratefully acknowledged. Farid M. Sroor is grateful to the ministry of Higher Educational Scientific Research (MHESR), Egypt, and the German Academic Exchange Service (DAAD), Germany, for a PhD scholarship within the German Egyptian Research Long-Term Scholarship (GERLS) program.

## References

- Recent review articles: (a) F. T. Edelmann, *Adv. Organomet. Chem.*, 2008, **57**, 183–352; (b) M. P. Coles, *Chem. Commun.*, 2009, 3659–3676; C. Jones, *Coord. Chem. Rev.*, 2010, **254**, 1273–1289; (c) A. A. Trifonov, *Coord. Chem. Rev.*, 2010, **254**, 1327–1347; (d) A. A. Mohamed, H. E. Abdou and J. P. Fackler Jr., *Coord. Chem. Rev.*, 2010, **254**, 1253–1259; (e) S. Collins, *Coord. Chem. Rev.*, 2011, **255**, 118–138; (f) F. T. Edelmann, *Adv. Organomet. Chem.*, 2013, **61**, 55–374.
- (a) F. T. Edelmann, *Chem. Soc. Rev.*, 2009, **38**, 2253–2268; (b) F. T. Edelmann, *Chem. Soc. Rev.*, 2012, **41**, 7657–7672.



- 3 A. Devi, *Coord. Chem. Rev.*, 2013, **257**, 3332–3384, and references cited therein.
- 4 (a) H. Fujita, R. Endo, A. Aoyama and T. Ichii, *Bull. Chem. Soc. Jpn.*, 1972, **45**, 1846–1852; (b) G. Himbert, M. Feustel and M. Jung, *Liebigs Ann. Chem.*, 1981, 1907–1927; (c) G. Himbert and W. Schwickerath, *Liebigs Ann. Chem.*, 1984, 85–97; (d) G. F. Schmidt and G. Süss-Fink, *J. Organomet. Chem.*, 1988, **356**, 207–211; (e) T.-G. Ong, J. S. O'Brien, I. Korobkov and D. S. Richeson, *Organometallics*, 2006, **25**, 4728; (f) X. Xu, J. Gao, D. Cheng, J. Li, G. Qiang and H. Guo, *Adv. Synth. Catal.*, 2008, **350**, 61–64; (g) W. Weingärtner, W. Kantlehner and G. Maas, *Synthesis*, 2011, 265–272; (h) W. Weingärtner and G. Maas, *Eur. J. Org. Chem.*, 2012, 6372–6382.
- 5 (a) H. Fujita, R. Endo, K. Murayama and T. Ichii, *Bull. Chem. Soc. Jpn.*, 1972, **45**, 1581; (b) W. Ried and M. Wegwitz, *Liebigs Ann. Chem.*, 1975, 89–94; (c) W. Ried and R. Schweitzer, *Chem. Ber.*, 1976, **109**, 1643–1649; (d) W. Ried and H. Winkler, *Chem. Ber.*, 1979, **112**, 384–388.
- 6 (a) P. Sienkiewicz, K. Bielawski, A. Bielawska and J. Palka, *Environ. Toxicol. Pharmacol.*, 2005, **20**, 118–124; (b) T. M. Sielecki, J. Liu, S. A. Mousa, A. L. Racanelli, E. A. Hausner, R. R. Wexler and R. E. Olson, *Bioorg. Med. Chem. Lett.*, 2001, **11**, 2201–2204; (c) C. E. Stephens, E. Tanious, S. Kim, D. W. Wilson, W. A. Schell, J. R. Perfect, S. G. Franzblau and D. W. Boykin, *J. Med. Chem.*, 2001, **44**, 1741–1748; (d) C. N. Rowley, G. A. DiLabio and S. T. Barry, *Inorg. Chem.*, 2005, **44**, 1983–1991.
- 7 (a) W.-X. Zhang, M. Nishiura and Z. Hou, *J. Am. Chem. Soc.*, 2005, **127**, 16788–16789; (b) S. Zhou, S. Wang, G. Yang, Q. Li, L. Zhang, Z. Yao, Z. Zhou and H.-B. Song, *Organometallics*, 2007, **26**, 3755–3761; (c) W.-X. Zhang and Z. Hou, *Org. Biomol. Chem.*, 2008, **6**, 1720–1730; (d) Z. Du, W. Li, X. Zhu, F. Xu and Q. Shen, *J. Org. Chem.*, 2008, **73**, 8966–8972; (e) C. N. Rowley, T.-G. Ong, J. Priem, D. S. Richeson and T. K. Woo, *Inorg. Chem.*, 2008, **47**, 12024–12031; (f) Y. Wu, S. Wang, L. Zhang, G. Yang, X. Zhu, Z. Zhou, H. Zhu and S. Wu, *Eur. J. Org. Chem.*, 2010, 326–332; (g) F. Zhang, J. Zhang, Y. Zhang, J. Hong and X. Zhou, *Organometallics*, 2014, **33**, 6186–6192.
- 8 (a) P. Dröse, C. G. Hrib and F. T. Edelmann, *J. Organomet. Chem.*, 2010, **695**, 1953–1956; (b) L. Xu, Y.-C. Wang, W.-X. Zhang and Z. Xi, *Dalton Trans.*, 2013, **42**, 16466–16469.
- 9 W. W. Seidel, W. Dachtler and T. Pape, *Z. Anorg. Allg. Chem.*, 2012, **638**, 116–121.
- 10 F. M. A. Sroor, C. G. Hrib, L. Hilfert and F. T. Edelmann, *Z. Anorg. Allg. Chem.*, 2013, **639**, 2390–2394.
- 11 F. M. Sroor, C. G. Hrib, L. Hilfert, P. G. Jones and F. T. Edelmann, *J. Organomet. Chem.*, 2015, **785**, 1–10.
- 12 S. Cotton, *Lanthanide and Actinide Chemistry*, John Wiley & Sons, Ltd, Chichester, UK, 2006.
- 13 G. F. Schmidt and G. Süss-Fink, *J. Organomet. Chem.*, 1988, **356**, 207–211.
- 14 M. Arrowsmith, M. R. Crimmin, M. S. Hill, S. L. Lomas, M. S. Heng, P. B. Hitchcock and G. Kociok-Köhn, *Dalton Trans.*, 2014, **43**, 14249–14256.
- 15 J. H. Freeman and M. L. Smith, *J. Inorg. Nucl. Chem.*, 1958, **7**, 224.
- 16 Stoe, *XAREA Program for Xray Crystal Data collection*, (XRED32 included in XAREA), Stoe, 2002.
- 17 (a) G. M. Sheldrick, *SHELXL-97 Program for Crystal Structure Refinement*, Universität Göttingen, Germany, 1997; (b) G. M. Sheldrick, *SHELXS-97 Program for Crystal Structure Solution*, Universität Göttingen, Germany, 1997.

